Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax by Fen Zhu, Jennifer L. Crombie, Wei Ni, Nguyet-Minh Hoang, Swati Garg, Liam Hackett, Stephen J. F. Chong, Mary C. Collins, Lixin Rui, James Griffin, Matthew S. Davids

Get full text

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies by Matthew S. Davids, Danielle M. Brander, Yesid Alvarado-Valero, Catherine S. Diefenbach, Daniel N. Egan, Shira N. Dinner, Nathalie Javidi-Sharifi, Monzr M. Al Malki, Kebede H. Begna, Vijaya Raj Bhatt, Sameem Abedin, Rachel J. Cook, Mary C. Collins, Carly Roleder, Edward C. Dominguez, Prabhu Rajagopalan, Sandra E. Wiley, Richard G. Ghalie, Alexey V. Danilov

Get full text

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia by Janani Ravikrishnan, Daisy Y. Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai, Shrilekha Misra, Charmelle D. Williams, John Sanchez, Andrew Mitchell, Suresh Satpati, Elizabeth Perry, Tierney Kaufman, Chaomei Liu, Arletta Lozanski, Gerard Lozanski, KerryA Rogers, Adam S. Kittai, Seema A. Bhat, Mary C. Collins, Matthew S. Davids, Nitin Jain, William G. Wierda, Rosa Lapalombella, John C. Byrd, Fenlai Tan, Yi Chen, Yu Chen, Yue Shen, Stephen P. Anthony, Jennifer A. Woyach, Deepa Sampath

Get full text